p.101 抽出テキスト

697. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77–82. https://doi.org/10.1056/ NEJM199507133330201 698. Dukes JW, Dewland TA, Vittinghoff E, Mandyam MC, Heckbert SR, Siscovick DS, et al. Ventricular ectopy as a predictor of heart failure and death. J Am Coll Cardiol 2015;66:101–9. https://doi.org/10.1016/j.jacc.2015.04.062 699. Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm 2010;7:865–9. https://doi.org/10.1016/j.hrthm. 2010.03.036 700. Hasdemir C, Ulucan C, Yavuzgil O, Yuksel A, Kartal Y, Simsek E, et al. Tachycardia-induced cardiomyopathy in patients with idiopathic ventricular arrhythmias: the incidence, clinical and electrophysiologic characteristics, and the predictors. J Cardiovasc Electrophysiol 2011;22:663–8. https://doi. org/10.1111/j.1540-8167.2010.01986.x 701. Slaven S, Garg L, Sabzwari R, Barrett C, Tumolo A, Cerbin L, et al. Burden of premature ventricular complexes and risk of cardiomyopathy: a crosssectional study. JACC Clin Electrophysiol 2025;11:894–903. https://doi.org/ 10.1016/j.jacep.2025.01.004 702. Bogun F, Crawford T, Reich S, Koelling TM, Armstrong W, Good E, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm 2007;4:863–7. https://doi.org/10.1016/j.hrthm.2007.03.003 703. Berruezo A, Penela D, Jauregui B, Soto-Iglesias D, Aguinaga L, Ordonez A, et al. Mortality and morbidity reduction after frequent premature ventricular complexes ablation in patients with left ventricular systolic dysfunction. Europace 2019;21:1079–87. https://doi.org/10.1093/europace/euz027 704. Yarlagadda RK, Iwai S, Stein KM, Markowitz SM, Shah BK, Cheung JW, et al. Reversal of cardiomyopathy in patients with repetitive monomorphic ventricular ectopy originating from the right ventricular outflow tract. Circulation 2005; 112:1092–7. https://doi.org/10.1161/CIRCULATIONAHA.105.546432 705. Prinzen FW, Auricchio A, Mullens W, Linde C, Huizar JF. Electrical management of heart failure: from pathophysiology to treatment. Eur Heart J 2022; 43:1917–27. https://doi.org/10.1093/eurheartj/ehac088 706. Cho SW, Gwag HB, Hwang JK, Chun KJ, Park KM, On YK, et al. Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy. Eur J Heart Fail 2019;21:643–51. https://doi.org/10.1002/ejhf.1427 707. Arnold JR, Kanagala P, Budgeon CA, Jerosch-Herold M, Gulsin GS, Singh A, et al. Prevalence and prognostic significance of microvascular dysfunction in heart failure with preserved ejection fraction. JACC Cardiovasc Imaging 2022;15:1001–11. https://doi.org/10.1016/j.jcmg.2021.11.022 708. Rush CJ, Berry C, Oldroyd KG, Rocchiccioli JP, Lindsay MM, Touyz RM, et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction. JAMA Cardiol 2021;6:1130–43. https://doi.org/10.1001/jamacardio.2021.1825 709. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan RS, et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. Eur Heart J 2018;39: 3439–50. https://doi.org/10.1093/eurheartj/ehy531 710. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194–9. https://doi.org/10. 1161/01.cir.0000035653.72855.bf 711. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA 2000;283:1295–302. https://doi.org/10. 1001/jama.283.10.1295 712. Ziff OJ, Samra M, Howard JP, Bromage DI, Ruschitzka F, Francis DP, et al. Beta-blocker efficacy across different cardiovascular indications: an umbrella review and meta-analytic assessment. BMC Med 2020;18:103. https://doi. org/10.1186/s12916-020-01564-3 713. Fox K, Ford I, Steg PG, Tendera M, Robertson M, Ferrari R, et al. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur Heart J 2009;30:2337–45. https://doi.org/10.1093/ eurheartj/ehp358 714. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med 1996;335:1107–14. https://doi.org/10.1056/NEJM199610103351504 715. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96: 856–63. https://doi.org/10.1161/01.cir.96.3.856 716. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet 2002;359:1269–75. https://doi.org/10.1016/S0140- 6736(02)08265-X 717. Wilson SR, Scirica BM, Braunwald E, Murphy SA, Karwatowska-Prokopczuk E, Buros JL, et al. Efficacy of ranolazine in patients with chronic angina observations from the randomized, double-blind, placebo-controlled MERLIN-TIMI (Metabolic Efficiency with ranolazine for less ischemia in non-ST-segment elevation acute coronary syndromes) 36 trial. J Am Coll Cardiol 2009;53:1510–6. https://doi.org/10.1016/j.jacc.2009.01.037 718. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814–21. https:// doi.org/10.1016/j.ehj.2004.06.034 719. Zhang L, Lu Y, Jiang H, Zhang L, Sun A, Zou Y, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol 2012;59:913–22. https://doi.org/10.1016/j.jacc.2011.11.027 720. Gao D, Ning N, Niu X, Hao G, Meng Z. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278–86. https://doi. org/10.1136/hrt.2010.208751 721. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52–60. https://doi.org/10.1161/01.cir.83.1.52 722. Matsumoto S, Henderson AD, Shen L, Kondo T, Yang M, Campbell RT, et al. Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. Eur J Heart Fail 2025;27:124–39. https://doi.org/10.1002/ejhf.3383 723. Matsumoto S, Kondo T, Yang M, Campbell RT, Docherty KF, de Boer RA, et al. Calcium channel blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction. Eur J Heart Fail 2023;25: 2202–14. https://doi.org/10.1002/ejhf.3044 724. Bonow RO, Maurer G, Lee KL, Holly TA, Binkley PF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011;364:1617–25. https://doi.org/10.1056/NEJMoa1100358 725. Jolicoeur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. J Am Coll Cardiol 2015;66:2092–100. https://doi.org/10.1016/j.jacc.2015.08.882 726. Panza JA, Holly TA, Asch FM, She L, Pellikka PA, Velazquez EJ, et al. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2013;61:1860–70. https://doi.org/10.1016/j.jacc.2013.02.014 727. Perera D, Ryan M, Morgan HP, Greenwood JP, Petrie MC, Dodd M, et al. Viability and outcomes with revascularization or medical therapy in ischemic ventricular dysfunction: a prespecified secondary analysis of the REVIVED-BCIS2 trial. JAMA Cardiol 2023;8:1154–61. https://doi.org/10. 1001/jamacardio.2023.3803 728. Ezad SM, McEntegart M, Dodd M, Didagelos M, Sidik N, Li Kam Wa M, et al. Impact of anatomical and viability-guided completeness of revascularization on clinical outcomes in ischemic cardiomyopathy. J Am Coll Cardiol 2024;84: 340–50. https://doi.org/10.1016/j.jacc.2024.04.043 729. Bloom JE, Vogrin S, Reid CM, Ajani AE, Clark DJ, Freeman M, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival. Eur Heart J 2025;46:72–80. https://doi.org/10.1093/eurheartj/ehae672 730. Volz S, Redfors B, Angeras O, Ioanes D, Odenstedt J, Koul S, et al. Long-term mortality in patients with ischaemic heart failure revascularized with coronary artery bypass grafting or percutaneous coronary intervention: insights from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2021;42:2657–64. https://doi.org/10.1093/eurheartj/ehab273 731. Sun LY, Gaudino M, Chen RJ, Bader Eddeen A, Ruel M. Long-term outcomes in patients with severely reduced left ventricular ejection fraction undergoing percutaneous coronary intervention vs coronary artery bypass grafting. JAMA Cardiol 2020;5:631–41. https://doi.org/10.1001/jamacardio.2020. 0239 732. Lopes RD, Alexander KP, Stevens SR, Reynolds HR, Stone GW, Pina IL, et al. Initial invasive versus conservative management of stable ischemic heart disease in patients with a history of heart failure or left ventricular dysfunction: Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026